Abstract:Background: Sacubitril valsartan and valsartan are the first new drugs approved for angiotensin receptor neprilysin lysine inhibitors (ARNIs) in outpatients with chronic heart failure (CHF) and hypertension. Compared with enalapril, sacubitril valsartan and valsartan have been shown to reduce the mortality and morbidity of cardiovascular diseases. However, there is little actual evidence regarding the efficacy of ARNIs in hypertensive patients with CHF. Methods: From January 2019 to January 2021, 60 patients with hypertension and chronic heart failure were diagnosed and treated in our hospital. The patients were randomly divided into an observation group and a control group, with 30 cases in each group. The control group was given valsartan, the observation group was given sacubitril valsartan, and both groups were treated for six months. The endothelium-dependent vasodilation (EDD) function of the brachial artery and serum nitric oxide (NO), endothelin-1 (ET-1), carotid artery intima-media thickness, and glomerular filtration, excess rate (eGFR), and left ventricular ejection fraction (LVEF) were compared between the two groups of patients before and after treatment. The serum adiponectin (APN), matrix metalloproteinase-9 (MMP-9), and brain natriuretic peptide (BNP) levels were compared before and after treatment. Results: The total effective rate of treatment in the research group was higher than that in the control group (P < 0.05). After treatment, the cardiac function indexes LVESD and LVEDD of the two groups of patients were lower than before treatment, and LVEF was higher than before treatment, and the improvement rate of the treatment group was better than that of the control group (P < 0.05). After treatment, the serum APN of the two groups was higher than before treatment, the levels of MMP-9 and BNP were lower than before treatment, and the improvement rate of patients in the treatment group was better than that of patients in the control group (P < 0.05). There was no statistically significant in the levels of EDD, NO, and ET-1 of the two groups of patients before treatment (P < 0.05). After treatment, compared with the control group, the EDD function and NO level of the research group were significantly increased (P < 0.05), and the level of ET-1 was significantly reduced (P < 0.05). There was no statistically significant difference in carotid artery intima-media thickness, glomerular filtration rate, and left ventricular ejection fraction before and after treatment in the two groups (P < 0.05). Conclusion: In the treatment of hypertension and chronic heart failure, sacubitril valsartan can improve the clinical symptoms of patients to the greatest extent and can significantly improve the levels of LVEF, LVEDD, NT-proBNP, heart function, and other indicators. Sacubitril valsartan can increase serum APN levels, reduce MMP-9 and BNP levels, and have good clinical effects. Sacubitril valsartan has a protective effect on the vascular endothelial function of patients with hypertension and CHF. However, these results need to be confirmed in studies involving more subjects and require longer follow-up times.

The comparative effects of valsartan and amlodipine on vWf levels and N/L ratio in patients with newly diagnosed hypertension

Effect of Valsartan on the Level of Vwf in Patients with Hypertension and Metabolic Syndrome

Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia

Impaired Endothelium-dependent Vasodilatation in Different Level of Risk in Essential Hypertension

Effects of Amlodipine and Valsartan on Blood Pressure Variability and Pulse Wave Velocity in Hypertensive Patients.

E0599 the Impact of Valsartan on Arterial Stiffness in Patients with Coronary Heart Disease and Hypertension

A5504 Comparison of the Effects of Valsartan and Amlodipine on the Characteristics of Ambulatory Blood Pressure in Hypertensive Patients

The Clinical Efficacy and Safety of Valsartan in Treatment of Patients with Essential Hypertensive

Comparison the Effects of Antihypertensive Agents on Arterial Structure and Function with Non-Dependent Blood Pressure Reduction

Influence of valsartan on Microalbuminuria of Essential Hypertensive Patients

Comparative Study to Effect of Valsartan and Amlodipine on Plasma Apelin-12 in Patients with Essential Hypertension

Effect of telmisartan on microalbuminuria in patients with hypertension

Effect of valsartan on chronotropic incompetence in hypertensive patients complicated with type 2 diabetes mellitus

Effects of valsartan hydrochlorothiazide on carotid intima-media thickness in patients with mild to moderate essential hypertension

Effects of monolithic compound preparations based on angiotensin II receptor antagonist on the prognosis of patients with hypertension

Effect of Valsartan on Postprandial Plasma Inflammatory Factors in Patients with Essential Hypertension

Clinical Study on Prevention of Artial Fibrillation by Valsartan in Patients with Essential Hypertension

Effects of the Valsartan/amlodipine Combination and Nifedipine Gastrointestinal Therapeutic System Monotherapy on Brachial Pulse Pressure and Radial Augmentation Index in Hypertensive Patients

Efficacy and Effectiveness of Valsartan/amlodipine and Valsartan/amlodipine/hydrochlorothiazide in Hypertension: Randomized Controlled Versus Observational Studies

The Difference between Sacubitril Valsartan and Valsartan on Vascular Endothelial Function, APN, MMP-9, and BNP Levels in Patients with Hypertension and Chronic Heart Failure

Effects of Telmisartan Combined with Nifedipine Controlled Release Tablet on Inflammatory Fac-Tors,vascular Endothelial Function and Left Ventricular Function in Patients with Coronary Heart Disease with Mild to Moderate Hypertension